Press Releases
Search
-
04 Sep 2025
Financial Information
First-Half 2025 Financial Results
Consolidated sales amounted to €2,044 million in the first-half of 2025 from €1,902 million in the prior year period, a +9.4% like-for-like growth.
-
18 Aug 2025
Business & Solutions
bioMérieux receives U.S. FDA 510(k) clearance and CLIA-waiver for Anterior Nasal Swab specimens, an additional sample type for use with the BIOFIRE® SPOTFIRE® R/ST Panel Mini
bioMérieux today announces that its BIOFIRE® SPOTFIRE® R/ST Panel Mini has received U.S. FDA 510(k) clearance and CLIA waiver for the addition of Anterior Nasal Swab as a validated specimen type for this panel.
-
16 Jun 2025
Mergers & Acquisitions
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.
-
03 Jun 2025
Business & Solutions
VETFIRE™: bioMérieux launches cutting-edge equine infectious respiratory disease testing
bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of VETFIRE™, a ready-to-use PCR kit that makes testing for equine infectious respiratory diseases easier and faster.
-
22 Apr 2025
Business & Solutions
WATCHFIRE™ by bioMérieux: a PCR test to detect viruses and bacteria in wastewater and respond to potential infectious disease outbreaks
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of its WATCHFIRE™ molecular testing solution. The WATCHFIRE™ Respiratory (R) Panel, targeting 22 pathogens*, will run on the BIOFIRE® FILMARRAY® TORCH instrument, integrated with FIREWORKS™ software, to deliver real-time trending of viruses and bacteria present in wastewater samples.
-
17 Apr 2025
Financial Information
First-Quarter 2025 Business Review
Consolidated sales totaled €1,098 million in the first quarter of 2025, up 13.7% as reported from €965 million in first quarter of 2024. Organic growth (at constant exchange rates and scope of consolidation) stood at +12.7%, above expectations.